Intrathecal Baclofen in Spasticity

  • H. Müller
  • J. Zierski
  • D. Dralle
  • O. Hoffmann
  • G. Michaelis


The syndrome of spasticity still confronts us with several unsolved problems in the theoretical as well as in the clinical field.


Multiple Sclerosis Muscle Tone Intrathecal Baclofen Intrathecal Catheter Intrathecal Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Angel RW, Hofmann WW (1963) The H reflex in normal, spastic and rigid subjects. Arch Neurol 8:591–596CrossRefGoogle Scholar
  2. 2.
    Andrews PLR, Wood KL (1986) Systemic baclofen stimulates gastric motility and secretion via a central action in the rat. Br J Pharmacol 89:461–467PubMedGoogle Scholar
  3. 3.
    Aptekar RG, Ford F, Bleck EE (1976) Light patterns as a mean of assessing and recording gait. Part 1: Methods and results in normal children. Dev Med Child Neurol 18:31–36PubMedCrossRefGoogle Scholar
  4. 4.
    Aptekar RG, Ford F, Bleck EE (1976) Light patterns as a mean of assessing and recording gait. Part 2: Results in children with cerebral palsy. Dev Med Child Neurol 18:37–40PubMedCrossRefGoogle Scholar
  5. 5.
    Aring CD (1973) Pain in multiple sclerosis. J Am Med Assoc 223:547CrossRefGoogle Scholar
  6. 6.
    Ashworth B (1964) Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 192:540–542PubMedGoogle Scholar
  7. 7.
    Ault A, Evans HE (1981) The depressant action of baclofen on the isolated spinal cord of the neonatal rat. Eur J Pharmacol 71:357–364PubMedCrossRefGoogle Scholar
  8. 8.
    Ault B, Nadler JV (1983) Anticonvulsant-like actions of baclofen in the rat hippocampal slice. Br J Pharmacol 78:701–708PubMedGoogle Scholar
  9. 9.
    Awapara J (1950) Detection and identification of metabolites in tissued by means of paper chromatography. Fed Proc 9:148Google Scholar
  10. 10.
    Badr GG, Matousek M, Frederiksen PK (1983) A quantitative EEG analysis of the effects of baclofen on man. Neuropsycho-biology 10:13–18CrossRefGoogle Scholar
  11. 11.
    Barker I, Grant I (1982) Convulsions after abrupt withdrawal of baclofen. Lancet II:556–557CrossRefGoogle Scholar
  12. 12.
    Basmajian JV (1975) Lioresal treatment of spasticity in multiple sclerosis. Am J Phys Med 54:175–177PubMedGoogle Scholar
  13. 13.
    Baum E (1981) Motographie 1. Bundesanstalt für Arbeitsschutz, WirtschaftsverlagGoogle Scholar
  14. 14.
    Bayerl JR, Gruia D (1985) Klinische Vergleichsstudie der Antispastika Memantin und Baclofen. Therapiewoche 35:5440–5444Google Scholar
  15. 15.
    Bazemore AW, Elliott KAC, Florey E (1957) Isolation of factor I. J Neurochem 1:334–339CrossRefGoogle Scholar
  16. 16.
    Ben-Ari J, Henry JL (1976) Effects of the parchlorphenyl derivate of GAB A on spinal neurones in the cat. J Physiol (Lond) 259:469–470Google Scholar
  17. 17.
    Benecke R, Conrad B, Höhne J, Meinck HM (1983) Quantitative analyses of the effect of antispastic drugs upon locomotor activity. Agressologie 24:147–149Google Scholar
  18. 18.
    Benecke R, Conrad B, Meinck HM (1984) Neue Erkenntnisse zur Pathophysiologie der Spastizität. In: Conrad B, Benecke R, Bauer HJ (eds) Die klinische Wertung der Spastizität. Schattauer, Stuttgart New York, pp 17–31Google Scholar
  19. 19.
    Benedito MAC, Leite JR (1981) Baclofen as an anticonvulsant in experimental models of convulsions. Exp Neurol 72:346–351PubMedCrossRefGoogle Scholar
  20. 20.
    Bergamini L, Riccio A, Bergamasco B (1966) Un farmaco ad azione antispastica della musculatura striata. Sperimentatione clinica di un derivato del GABA. Minerva Med 57:2723–2725PubMedGoogle Scholar
  21. 21.
    Birkmayer W (1972) Spasticity — a topical survey. Huber, WienGoogle Scholar
  22. 22.
    Bousquet P, Feldman J, Bloch R, Schwartz J (1981) The central hypotensive action of baclofen in the anaesthetized cat. Eur J Pharmacol 76:193–201PubMedCrossRefGoogle Scholar
  23. 23.
    Bowery NG (1982) Baclofen 10 years on. Trends Pharmacol Sci 3:400–403CrossRefGoogle Scholar
  24. 24.
    Bowery NG (1983) Le Baclofene tel qu’il se présente au bout de dix ans. Gaz Med Fr 90:2891–2897Google Scholar
  25. 25.
    Bowery NG, Hill DR, Hudson AL, Doble A, Middlemiss DN, Shaw J, Turnhull M (1980) (-)Baclofen decreases neurotransmitter release in the mammalian CNS by action at a novel GABA receptor. Nature 283:92–94PubMedCrossRefGoogle Scholar
  26. 26.
    Brill B, Greve J (1985) Photographische Bewegungsanalyse bei neurologischen Störungen und ihre Bedeutung für die Rehabilitation. In: Schimrigk K, Haaß A (eds) Zentrale Bewegungsstörungen — Arzneimittelinterferenzen. Perimed, Erlangen, pp 37–54Google Scholar
  27. 27.
    Brodie BB (1960) The importance of dissociation constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther 130:20–25PubMedGoogle Scholar
  28. 28.
    Burke D, Andrews C, Knowles L (1971) The action of a GABA derivate in human spasticity. J Neurol Sci 14:199–208PubMedCrossRefGoogle Scholar
  29. 29.
    Burke D, Gillies DJ, Lance JW (1970) The quadriceps stretch reflex in human spasticity. J Neurol Neurosurg Psychiatry 33:216–223PubMedCrossRefGoogle Scholar
  30. 30.
    Capek R, Esplin B (1982) Baclofen-induced decrease of excitability of primary afferents and depression of monosynaptic transmission in cat spinal cord. Can J Physiol Pharmacol 60:160–167PubMedCrossRefGoogle Scholar
  31. 31.
    Cartlidge NEF, Hudgson P, Weightman D (1974) A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci 23:17–24PubMedCrossRefGoogle Scholar
  32. 32.
    Cendrowski W, Sobczyk W (1977) Clonazepam, baclofen and placebo in the treatment of spasticity. Eur Neurol 16: 257–262PubMedCrossRefGoogle Scholar
  33. 33.
    Chahl LA, Walker SB (1980) The effect of baclofen on the cardiovascular system of the rat. Br J Pharmacol 69:631–637PubMedGoogle Scholar
  34. 34.
    Coletti A, Mandelli A, Minoli G, Tredici EP (1980) Post-anoxic action myoclonus (Lance-Adams syndrome) treated with levodopa and gabaergic drugs. J Neurol 223:67–70PubMedCrossRefGoogle Scholar
  35. 35.
    Conrad B, Benecke R (1985) Bewegungsanalyse zentralmotorischer Krankheiten als Mittel der Therapiekontrolle. In: Schimrigk K, Haaß A (eds) Zentrale Bewegungsstörungen — Arzneimittelinterferenzen. Perimed, Erlangen, pp 55–63Google Scholar
  36. 36.
    Conrad B, Benecke R, Meinck HM (1984) Qualitative and quantitative Aspekte der spastischen Bewegungsstörung der unteren Extremität. In: Conrad B, Benecke R, Bauer HJ (eds) Die klinische Wertung der Spastizität. Schattauer, Stuttgart New York, pp 73–84Google Scholar
  37. 37.
    Corli O, Roma G, Bacchini M, Battagliarin G, Di Piazza D, Brambilla C, Grossi E (1984) Double-blind placebo-controlled trial of baclofen, alone and in combination, in patients undergoing voluntary abortion. Clin Ther 6:800–807PubMedGoogle Scholar
  38. 38.
    Corston RN, Johnson F, Godwin-Austen RB (1981) The assessment of drug treatment of spastic gait. J Neurol Neurosurg Psychiatry 44:1035–1039PubMedCrossRefGoogle Scholar
  39. 39.
    Curtis DR, Game CJA, Johnston GAR, McCulloch RM (1974) Central effects of β-(p-chlorphenyl)-gamma-aminobutyric acid. Brain Res 70:493–500PubMedCrossRefGoogle Scholar
  40. 40.
    Curtis DR, Lodge D, Bornstein JC, Peet MJ (1981) Selective effect of (-)baclofen on spinal synaptic transmission in the cat. Exp Brain Res 42:158–170PubMedCrossRefGoogle Scholar
  41. 41.
    Curtis DR, Johnston GAR (1974) Amino acid transmitters in the mammalian central nervous system. Ergeb Physiol 69:97–188PubMedGoogle Scholar
  42. 42.
    Cutting DA, Jordan CC (1975) Alternative approach to analgesia: Baclofen as a model compound. Br J Pharmacol 54:171–176PubMedGoogle Scholar
  43. 43.
    Davidoff RA (1980) Effects of baclofen on synaptic activity in the spinal cord. In: Feldman RG, Young RR, Koella WP (eds) Spasticity: Disordered motor control. Year Book, Chicago, pp 421–436Google Scholar
  44. 44.
    Davidoff RA, Sears ES (1974) The effects of Lioresal on synaptic activity in the isolated spinal cord. Neurology 24:957–963PubMedGoogle Scholar
  45. 45.
    Davies J (1981) Selective depression of synaptic excitation in cat spinal neurons by baclofen: an iontophoretic study. Br J Pharmacol 72:373–384PubMedGoogle Scholar
  46. 46.
    Defeudis FV (1982) Studies on GABA and cardiovascular function using in vivo and in vitro technics. Drug Develop Res 2:507–517CrossRefGoogle Scholar
  47. 47.
    Defeudis FV (1983) Gamma-aminobutyric acid and cardiovascular function. Experientia 39:845–849PubMedCrossRefGoogle Scholar
  48. 48.
    Delwaide PJ (1985) Electrophysiological analysis of the mode of action of muscle relaxants in spasticity. Ann Neurol 17:90–95PubMedCrossRefGoogle Scholar
  49. 49.
    Delwaide PJ, Cordonnier M (1977) Traitement médicamenteux de la spasticité. Méd Hyg 35:2053–2061Google Scholar
  50. 50.
    Delwaide PJ, Cordonnier M, Gadea-Ciria M (1978) Excitability relationship between lower limb myotactic arcs in spasticity. J Neurol Neurosurg Psychiatry 41:636–641PubMedCrossRefGoogle Scholar
  51. 51.
    Delwaide PJ, Martinelli P, Crenna P (1980) Clinical neurophysiological measurement of spinal reflex activity. In: Feldman RG, Young GG, Koalla WP (eds) Spasticity: disordered motor control. Year Book, Chicago, pp 345–371Google Scholar
  52. 52.
    Delwaide P, Schoenen J (1984) Auswahl des Antispastikums unter besonderer Berücksichtigung der jeweils vorliegenden Pathophysiologie der Spastizität. In: Conrad B, Benecke R, Bauer HJ (eds) Die klinische Wertung der Spastizität. Schattauer, Stuttgart New York, pp 91–96Google Scholar
  53. 53.
    Di Chiro G (1966) Observations on the circulation of the cerebrospinal fluid. Acta Radiol [Diagn] (Stockh) 5:988–996Google Scholar
  54. 54.
    Dickinson AH, Brewer CM, Hayes NA (1985) Effect of topical baclofen on C-fibre-evoked neuronal activity in the rat dorsal horn. Neuroscience 14:557–562CrossRefGoogle Scholar
  55. 55.
    Dimitrijevic MR, Nathan PW (1967) Studies of spasticity in man. 2. Analysis of stretch reflexes in spasticity. Brain 90:333–358PubMedCrossRefGoogle Scholar
  56. 56.
    Dimitrijevic MR, Sherwood AM (1980) Spasticity: medical and surgical treatment. Neurology 30:19–27PubMedGoogle Scholar
  57. 57.
    Drayer BP, Rosenbaum AE (1978) Studies of the third circulation. J Neurosurg 48:946–953PubMedCrossRefGoogle Scholar
  58. 58.
    Duncan GW, Shahani BT, Young RR (1976) An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions: a double-blind cross over study. Neurology (Minneapolis) 26:441–446Google Scholar
  59. 59.
    Dunlap K (1981) Two types of gamma-aminobutyric acid receptors on embryonic sensory neurones. Br J Pharmacol 74:579–585PubMedGoogle Scholar
  60. 60.
    Enna SJ, Maggi A (1979) Biochemical pharmacology of gabaergic agonists. Life Sci 24:1727–1738PubMedCrossRefGoogle Scholar
  61. 61.
    Fehr HU, Bein HJ (1974) Sites of action of a new muscle relaxant (baclofen, Lioresal, CIBA 34 647-Ba). J Int Med Res 2:36–47Google Scholar
  62. 62.
    Feldman RG, Kelly-Hayes M, Comony JP, Foley JM (1978) Baclofen for spasticity in multiple sclerosis: double-blind crossover and three-year study. Neurology 28:1094–1098PubMedGoogle Scholar
  63. 63.
    Florey E (1954) An inhibitory and an excitatory factor of mammalian central nervous system, and their actions on a single sensory neuron. Arch Int Physiol 62:33–53PubMedCrossRefGoogle Scholar
  64. 64.
    Foerster O (1911) Die Behandlung spastischer Lähmungen durch Resektion hinterer Rückenmarkswurzeln. Ergeb Chir 2:174–209Google Scholar
  65. 65.
    Fox S, Krnjević K, Morris ME, Puil E, Werman R (1978) Action of baclofen on mammalian synaptic transmission. Neuroscience 3:495–515PubMedCrossRefGoogle Scholar
  66. 66.
    From A, Heltberg A (1975) A double-blind trial with baclofen and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 51:158–166PubMedCrossRefGoogle Scholar
  67. 67.
    Fromm GH, Terrence CF, Chattha AS, Glass JD (1980) Baclofen in trigeminal neuralgia. Its effect on the spinal trigeminal nucleus: a pilot study. Arch Neurol 37:768–771PubMedCrossRefGoogle Scholar
  68. 68.
    Fung SC, Swarbrick MJ, Fillenz M (1985) Effect of baclofen on in vitro noradrenaline release from rat hippocampus and cerebellum: an action at an alpha2-adrenoceptor. Neurochem Int 7:155–163PubMedCrossRefGoogle Scholar
  69. 69.
    Fukuda H, Kudo Y, Ono H (1977) Effects of β-(p-chlorphenyl-)GABA (baclofen) on spinal synaptic activity. Eur J Pharmacol 44:17–24PubMedCrossRefGoogle Scholar
  70. 70.
    Gemer HJ, Rauda DW, Witterstätter K (1979) Die soziale Situation von Querschnittgelähmten. Eine empirische Untersuchung. Rehabilitation 18:135–149Google Scholar
  71. 71.
    Gerschenfeld HM (1973) Chemical transmission in invertebrate central nervous systems and neuromuscular junction. Physiol Rev 53:1–119PubMedGoogle Scholar
  72. 72.
    Ghose K, Holmes KM, Matthewson K (1980) Complications of baclofen overdosage. Postgrad Med J 56:865–867PubMedCrossRefGoogle Scholar
  73. 73.
    Gillis RA, Yamada KA, Dimicco JA, Williford DJ, Segal SA, Hamosh P, Norman WP (1984) Central gamma-aminobutyric acid involvement in blood pressure control. Fed Proc 43:32–38PubMedGoogle Scholar
  74. 74.
    Gray JA, Metz A, Goodwin GM, Green AR (1986) The effect of GABA-mimetic drugs, progabide and baclofen, on the biochemistry and function of 5-hydroxytryptamine and noradrenaline. Neuropharmacology 25:711–716PubMedCrossRefGoogle Scholar
  75. 75.
    Green AR (1986) Changes in GABA biochemistry and seizure threshold. Ann NY Acad Sci 462:105–119PubMedCrossRefGoogle Scholar
  76. 76.
    Hammond DL, Drower EJ (1984) Effects of intrathecally administered THIP, baclofen and muscimol on nociceptive threshold. Eur J Pharmacol 103:121–125PubMedCrossRefGoogle Scholar
  77. 77.
    Hassan N, McLellan DL (1980) Double-blind comparison of single doses of DS 103-282, baclofen and placebo for suppression of spasticity. J Neurol Neurosurg Psychiatry 43:1132–1136PubMedCrossRefGoogle Scholar
  78. 78.
    Hassler R (1981) Neuronale Grundlagen der spastischen Tonussteigerung. In: Bauer HJ, Koella WP, Struppler A (eds) Therapie der Spastik. Verlag für angewandte Wissenschaften, München, pp 11–38Google Scholar
  79. 79.
    Hattab JR (1980) Review of European trials with baclofen. In: Feldman RG, Young RR, Koella WP (eds) Spasticity: disordered motor control. Symposia Specialists, Miami, pp 71–75Google Scholar
  80. 80.
    Hayashi T, Nagai K (1956) Action of amino acids on the motor cortex of higher animals, especially γ-amino-β oxybutyric acid as a real inhibitory principle in brain. Proc XX Int Physiol Congress:410Google Scholar
  81. 81.
    Head H, Riddoch G (1917) The automatic bladder, excessive sweating and some other reflex conditions in gross injuries of the spinal cord. Brain 40:188–263CrossRefGoogle Scholar
  82. 82.
    Hedley DW, Maroun JA, Espir MLE (1975) Evaluation of baclofen for spasticity in multiple sclerosis. Postgrad Med J 51:615–622PubMedCrossRefGoogle Scholar
  83. 83.
    Henry JL (1980) Pharmacologic studies on baclofen in the spinal cord of the cat. In: Feldman RG, Young RR, Koella WP (eds) Spasticity: disordered motor control. Year Book, Chicago, pp 437–452Google Scholar
  84. 84.
    Herman R (1970) The myotactic reflex: Clinico-physiological aspects of spasticity and contracture. Brain 99:237–312Google Scholar
  85. 85.
    Howe JR, Zieglgänsberger W (1986) D-Baclofen does not antagonize the actions of l-baclofen on rat neocortical neurons in vitro. Neurosci Lett 72:99–104PubMedCrossRefGoogle Scholar
  86. 86.
    Hudgson P, Weightman D (1971) Baclofen in the treatment of spasticity. Br Med J 4:15–18PubMedCrossRefGoogle Scholar
  87. 87.
    Hyser CL, Drake ME (1984) Status epilepticus after baclofen withdrawal. J Natl Med Assoc 76:533–538PubMedGoogle Scholar
  88. 88.
    Jensen D (1979) Spastiske nedre urinveier. Er det indisert med. In: Dietrichson P, Nyberg-Hansen R (eds) Spastisotet og rigiditet. Cyba-Geigy, Switzerland, pp 259–271Google Scholar
  89. 89.
    Johnston GAR, Hailstone MH, Freeman CG (1980) Baclofen: stereo-selective inhibition of excitant amino acid release. J Pharm Pharmacol 32:230–231PubMedCrossRefGoogle Scholar
  90. 90.
    Jones RF, Burke D, Marosszeky JE, Gillies JD (1970) A new agent for the control of spasticity. J Neurol Neurosurg Psychiatry 33:464–468PubMedCrossRefGoogle Scholar
  91. 91.
    Jones RF, Lance JW (1976) Baclofen in the long-term management of spasticity. Med J Aust 1:654–657PubMedGoogle Scholar
  92. 92.
    Kehoe JS, Marder E (1976) Identification and effects of neural transmitters in invertebrates. Annu Rev Pharmacol 16:245–268CrossRefGoogle Scholar
  93. 93.
    Koella WP (1980) Baclofen: its general pharmacology and neuropharmacology. In: Feldman RG, Young GG, Koalla WP (eds) Spasticity: disordered motor control. Year Book, Chicago, pp 383–396Google Scholar
  94. 94.
    Krogsgaard-Larsen P, Scheel-Kruger J, Kofod H (1979) GABA-neurotransmitters. Academic Press, New YorkGoogle Scholar
  95. 95.
    Krnjevic K (1974) Chemical nature of synaptic transmission in vertebrates. Physiol Rev 54:418–540Google Scholar
  96. 96.
    Kurnick NB (1956) Autonomic hyperreflexia and its control in patients with spinal cord lesions. Ann Intern Med 44:678–686PubMedGoogle Scholar
  97. 97.
    Lalley PM (1980) Unexpected disinhibitory effects of baclofen on cardiovascular and respiratory neurons. Brain Res Bull 5:565–573CrossRefGoogle Scholar
  98. 98.
    Lalley PM (1980) Inhibition of depressor cardiovascular reflexes by a derivate of gamma-aminobutyric acid (GABA) and by general anesthetics with suspected GABA-mimetic effects. J Pharmacol Exp Ther 215:418–425PubMedGoogle Scholar
  99. 99.
    Lalley PM (1983) Biphasic effects of baclofen on phrenic motoneurons: possible involvement of two types of gamma-aminobutyric acid (GABA) receptors. J Pharmacol Exp Ther 226:616–624PubMedGoogle Scholar
  100. 100.
    Lalley PM (1986) Effects of baclofen and gamma-aminobutyric acid on different types of medullary respiratory neurons. Brain Res 376:392–395PubMedCrossRefGoogle Scholar
  101. 101.
    Lang HD, Dürr W, Hoffmann J, Koeth R (1980) Post-clinical follow-up of spinal patients through domestic check-ups. Paraplegia 18:140–144PubMedCrossRefGoogle Scholar
  102. 102.
    Lanz E, Däubler F, Eissner D, Brod KH, Theiß D (1986) Der Einfluß der spinalen Liquordynamik auf die subarachnoidale Ausbreitung rückenmarksnah applizierter Substanzen. Reg Anaesth 9:4–8PubMedGoogle Scholar
  103. 103.
    Levine IM, Jossmann PB, DeAngelis V (1972) Quantitative Wirkungsbeurteilung von CIBA 34 647 Ba. Ein vorläufiger Bericht. In: Birkmayer W (ed) Aspekte der pp 50–70Google Scholar
  104. 104.
    Levy RA, Proudfit HK (1977) The analgesic action of baclofen. J Pharmacol Exp Ther 202:437–442PubMedGoogle Scholar
  105. 105.
    Lipscomb DJ, Meredith TJ (1980) Baclofen overdose. Postgrad Med J 56:108–109PubMedCrossRefGoogle Scholar
  106. 106.
    Lloyd KG, Bartholini G, Morselli P (1986) GABA and mood disorders. Raven Press, New YorkGoogle Scholar
  107. 107.
    Lloyd KG, Pilc A (1984) Chronic antidepressants and GABA synapses. Neuropharmacology 23:841–842CrossRefGoogle Scholar
  108. 108.
    Löscher W (1982) Comparative assay of anticonvulsant and toxic potencies of sixteen GABAmimetic drugs. Neuropharmacology 21:803–810PubMedCrossRefGoogle Scholar
  109. 109.
    Lowitzsch K, D’Amato P, Krämer G (1981) Wirkung von Lioresal auf Kontraktion und isometrische Kraft der quergestreiften Muskulatur. In: Bauer HJ, Koella WP, Struppler A (eds) Therapie der Spastik. Verlag für angewandte Wissenschaften, München, pp 173–175Google Scholar
  110. 110.
    Martensson A, Knutsson E (1981) Effects of baclofen on different components in the disorganized motor control in spastic paresis. In: Bauer HJ, Koella WP, Struppler A (eds) Therapie der Spastik. Verlag für angewandte Wissenschaften, München, pp 193–199Google Scholar
  111. 111.
    Matthews PBC (1959) The dependence of tension upon extension in the stretch reflex of the soleus muscle in the decerebrate cat. J Physiol (Lond) 147:521–546Google Scholar
  112. 112.
    Matthews WB (1966) Ratio of maximum H reflex to maximum M response as a measure of spasticity. J Neurol Neurosurg Psychiatry 29:201–204PubMedCrossRefGoogle Scholar
  113. 113.
    May CR (1983) Baclofen overdose. Ann Emerg Med 12:171–173PubMedCrossRefGoogle Scholar
  114. 114.
    McDowell FH (1981) Treatment of spasticity. Drugs 22:401–408PubMedCrossRefGoogle Scholar
  115. 115.
    McLellan DL, Selwyn M, Cooper IS (1978) Time course of clinical and physiological effects of stimulation of the cerebellar surface in patients with spasticity. J Neurol Neurosurg Psychiatry 41:150–160PubMedCrossRefGoogle Scholar
  116. 116.
    Meldrum B (1984) GABAergic agents as anticonvulsants in baboons with photosensitive epilepsy. Neurosci Lett 47:345–349PubMedCrossRefGoogle Scholar
  117. 117.
    Michel M (1983) Rehabilitationsverlauf nach Schädelhirntrauma bei Kindern — eine neurophysiologische Studie. Rehabilitation 22:137–148PubMedGoogle Scholar
  118. 118.
    Milhorat TH (1975) The third circulation revisited. J Neurosurg 42:628–635PubMedCrossRefGoogle Scholar
  119. 119.
    Misgeld U, Klee MR, Zeise ML (1981) Baclofen blockiert die GABAerge Hemmung im Hippocampus. In: Bauer HJ, Koella WP, Struppler A (eds) Therapie der Spastik. Verlag für angewandte Wissenschaften, München, pp 111–114Google Scholar
  120. 120.
    Morselli P, Lloyd KG (1986) Epilepsy and GABA receptor agonists: Basic and clinical research. Raven Press, New YorkGoogle Scholar
  121. 121.
    Müller H, Vogelberger W, Aigner K, Herget HF, Hempelmann G (1983) Kontinuierliche peridurale Opiatapplikation mit einer implantierten Pumpe. Implantationstechnik und erste Ergebnisse. Reg Anaesth (Anaesthesist) 6:47–51Google Scholar
  122. 122.
    Neuhäuser G (1975) Methods of assessing and recording motor skills and movement patterns. Dev Med Child Neurol 17:369–386PubMedCrossRefGoogle Scholar
  123. 123.
    Noth J, Friedemann HH (1984) Die Analyse langlatenziger Dehnungsreflexe zur Erkennung spastischer Syndrome. In: Conrad B, Benecke R, Bauer HJ (eds) Die klinische Wertung der Spastizität. Schattauer, Stuttgart, New York, pp 113–121Google Scholar
  124. 124.
    Olpe HR, Baudry M, Fagni L, Lynch G (1982) The blocking action of baclofen on excitatory transmission in the rat hippocampal slice. J Neurosci 2:698–703PubMedGoogle Scholar
  125. 125.
    Olpe HR, Demiéville H, Baltzer H, Bencze WL, Koella WP, Wolf P, Haas HL (1978) The biological activity of d-and l-baclofen. Eur J Pharmacol 52:133–136PubMedCrossRefGoogle Scholar
  126. 126.
    Olsen PZ, Diamantopoulos E (1967) Excitability of spinal motor neurones in normal subjects and patients with spasticity, Parkinsonian rigidity and cerebellar hypotonia. J Neurol Neurosurg Psychiatry 30:325–331PubMedCrossRefGoogle Scholar
  127. 127.
    Otsuka M, Yanagisawa M (1980) The effect of substance P and baclofen on motorneurons of isolated spinal cord of the newborn rat. J Exp Biol 89:201–214PubMedGoogle Scholar
  128. 128.
    Panerai AE, Massei R, De Silva E, Sacerdote P, Monza G, Mantegazza P (1985) Baclofen prolongs the analgesic effect of fentanyl in man. Br J Anaesth 57:954–955PubMedCrossRefGoogle Scholar
  129. 129.
    Paulson GW (1976) Overdose of Lioresal. Neurology 26:1105–1106PubMedGoogle Scholar
  130. 130.
    Pedersen E, Arlien-Soborg P, Grynderup V (1970) GABA derivate in spasticity. Acta Neurol Scand 46:257–266PubMedCrossRefGoogle Scholar
  131. 131.
    Pedersen A, Arlien-Soborg P, Mai P (1974) The mode of action of the GABA derivate baclofen in human spasticity. Acta Neurol Scand 50:665–680PubMedCrossRefGoogle Scholar
  132. 132.
    Penn RD, Paice JA, Gottschalk W, Ivankovich AD (1984) Cancer pain relief using chronic morphine infusion. Early experience with a programmable implanted drug pump. J Neurosurg 61:302–306PubMedCrossRefGoogle Scholar
  133. 133.
    Persson B, Henning M (1980) Central cardiovascular and biochemical effects of baclofen in the conscious rat. J Pharm Pharmacol 32:417–422PubMedCrossRefGoogle Scholar
  134. 134.
    Piercy M, Hollister RP (1979) Effects of intravenous baclofen on dorsal horn neurons in spinal cat. Eur J Pharmacol 53:379–382CrossRefGoogle Scholar
  135. 135.
    Pinto ODS, Polikar M, Debono G (1972) Results of international clinical trials with Lioresal. Postgrad Med J 48:18–23Google Scholar
  136. 136.
    Polacek L, Schuppien W (1972) Vier Jahre in der Behandlung der multiplen Sklerose mit Lioresal. In: Birkmayer W (ed) Aspekte der Muskelspastik. Huber, Bern Stuttgart Wien, pp 123–127Google Scholar
  137. 137.
    Potashner SJ (1978) Baclofen: effects on aminoacid release. Can J Physiol Pharmacol 56:150–156PubMedCrossRefGoogle Scholar
  138. 138.
    Prosiegel M, Neu I, Pfaffenrath V, Nahme M (1982) Thrombozytenaggregation und Multiple Sklerose. Nervenarzt 53:227–230PubMedGoogle Scholar
  139. 139.
    Roberts E, Chase TN, Tower DB (1976) GABA in nervous system function. Raven Press, New YorkGoogle Scholar
  140. 140.
    Roberts E, Frankel S (1950) γ-aminobutyric acid in the brain. Fed Proc 9:219Google Scholar
  141. 141.
    Sachais BA, Logue JN, Carey MS (1977) Baclofen, a new antispastic drug. Arch Neurol 34:422–428PubMedCrossRefGoogle Scholar
  142. 142.
    Saito K, Konishi S, Otsuko M (1975) Antagonism between Lioresal and substance P in the rat spinal cord. Brain Res 97:177–182PubMedCrossRefGoogle Scholar
  143. 143.
    Sawa GM, Paty DW (1979) The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci 6:351–356PubMedGoogle Scholar
  144. 144.
    Sawynok J (1986) Baclofen activates two distinct receptors in the rat spinal cord and guinea pig ileum. Neuropharmacology 25: 795–798PubMedCrossRefGoogle Scholar
  145. 145.
    Sawynok J, Dickson C (1984) D-Baclofen: Is it an antagonist at baclofen receptors? Prog Neuropsychopharmacol Biol Psychiatry 8:729–731PubMedCrossRefGoogle Scholar
  146. 146.
    Sawynok J, Dickson C (1985) D-Baclofen is an antagonist at Baclofen receptors mediating antinociception in the spinal cord. Pharmacology 31:248–259PubMedCrossRefGoogle Scholar
  147. 147.
    Sawynok J, Dickson C (1985) Evidence for the involvement of descending noradrenergic pathways in the antinociceptive effect of baclofen. Brain Res 335:89–97PubMedCrossRefGoogle Scholar
  148. 148.
    Sawynok J, Reid A (1986) Clonidine reverses baclofen-induced increases in noradrenaline turnover in rat brain. Neurochem Res 11:723–731PubMedCrossRefGoogle Scholar
  149. 149.
    Schepelmann F (1974) Dissociation of motoricity in cerebral lesions. In: Umbach W, Koepchen P (eds) Central-rhythmic and regulation. Hippokrates, Stuttgart, pp 295–301Google Scholar
  150. 150.
    Schepelmann F (1975) The treatment of spasticity by Foerster’s operation. In: Klug W, Brock M, Klinger M, Spoerri O (eds) Meningiomas-Multiple sclerosis-Forensic problems in neurosurgery. Springer, Berlin Heidelberg New York, pp 417–419Google Scholar
  151. 151.
    Schepelmann F (1979) Rhythmic patterns of motor activity after lesions of the central nervous system in man. Acta Neurochir (Wien) 49:153–189CrossRefGoogle Scholar
  152. 152.
    Schepelmann F (1976) Human motor activity in decerebrate states and their sequelae. Acta Neurochir (Wien) 46:185–217CrossRefGoogle Scholar
  153. 153.
    Seyfert S, Straschill M (1982) Elektroenzephalographische Veränderungen unter Baclofen. Z Elektroenzeph Elektromyogr 13:161–166Google Scholar
  154. 154.
    Sill JC, Schumacher K, Southorn K, Reuter J, Yaksh TL (1986) Bradycardia and hypotension associated with baclofen used during general anesthesia. Anesthesiology 64:255–258PubMedCrossRefGoogle Scholar
  155. 155.
    Sindou M, Millet MF, Moretiemais J, Eysette M (1981) Results of selective posterior rhizotomy in the treatment of painful and spastic paraplegia secondary to multiple sclerosis. Appl Neurophysiol 45:335–340Google Scholar
  156. 156.
    Smith DF (1984) Stereoselectivity of spinal neurotransmission: effects of baclofen enantiomer on tail-flick reflex in rats. J Neural Transm 60:63–67PubMedCrossRefGoogle Scholar
  157. 157.
    Smolenski C, Muff S, Smolenski-Kautz S (1981) A double-blind comparative trial of a new muscle relaxant, tizanidine (DS 103-284) and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 7:374–383PubMedGoogle Scholar
  158. 158.
    Steardo L, Leo A, Marano E (1984) Efficacy of baclofen in trigeminal neuralgia and some other painful conditions. Eur Neurol 23:51–55PubMedCrossRefGoogle Scholar
  159. 159.
    Struppler A (1981) Klinik und Physiologie der Spastik. In: Bauer HJ, Koella WP, Struppler A (eds) Therapie der Spastik. Verlag für angewandte Wissenschaften, München, pp 115–124Google Scholar
  160. 160.
    Swartzwelder HS, Bragdon AC, Sutch CP, Ault B, Wilson WA (1986) Baclofen suppresses hippocampal epileptiform activity at low concentrations without suppressing synaptic transmission. J Pharmacol Exp Ther 237:881–887PubMedGoogle Scholar
  161. 161.
    Terrence CF, Fromm GH (1981) Complications of baclofen withdrawal. Arch Neurol 38:588–589PubMedCrossRefGoogle Scholar
  162. 162.
    Terrence CF, Fromm GH, Roussan MS (1983) Baclofen: Its effect on seizure frequency. Arch Neurol 40:28–29PubMedCrossRefGoogle Scholar
  163. 163.
    Warren SA, Warren KG (1981) Multiple sclerosis and related diseases: a relationship to diabetes mellitus. Can J Neurol Sci 8:35–39PubMedGoogle Scholar
  164. 164.
    Wesendanger M (1967) Morphological, electrophysiological and pathological aspects of interneurones: In: Widén L (ed) Recent advances in clinical neurophysiology. Elsevier, Amsterdam, pp 47–58Google Scholar
  165. 165.
    Williford DJ, DiMicco JA, Gillis RA (1980) Evidence for the presence of a tonically active forebrain GABAsystem influencing central sympathetic outflow in the cat. Neuropharmacology 19:245–250PubMedCrossRefGoogle Scholar
  166. 166.
    Wilson PR, Yaksh TL (1978) Baclofen is antinociceptive in the spinal intrathecal space of animals. Eur J Pharmacol 51:323–330PubMedCrossRefGoogle Scholar
  167. 167.
    Yaksh TL, Müller H (1982) Spinal opiate analgesia. Experimental and clinical studies. Springer, Berlin Heidelberg New YorkGoogle Scholar
  168. 168.
    Yaksh TL, Reddy SV (1981) Studies in the primate on the analgetic effects associated with intrathecal actions of opiates, alphaadrenergic agonists and baclofen. Anesthesiology 54:451–467PubMedCrossRefGoogle Scholar
  169. 169.
    Yamada KA, Norman WP, Hamosh P, Gillis RA (1982) Medullary ventral surface GABA receptors affect respiratory and cardiovascular function. Brain Res 248:71–78PubMedCrossRefGoogle Scholar
  170. 170.
    Young RR, Delwaide PJ (1981) Drug therapy: spasticity. N Engl J Med 304:96–99PubMedCrossRefGoogle Scholar
  171. 171.
    Zander KJ, Puerner K, Struppler A (1981) Motorische Kontrollmechanismen beim hemispastischen Syndrom. Effekte von Baclofen. In: Bauer HJ, Koella WP, Struppler A (eds) Therapie der Spastik. Verlag für angewandte Wissenschaften, München, pp 149–162Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • H. Müller
  • J. Zierski
  • D. Dralle
  • O. Hoffmann
  • G. Michaelis

There are no affiliations available

Personalised recommendations